Riga, Latvia – July 31, 2024
The fully-robotic tele-operated system, Sentante, has successfully completed its first human clinical cases in the recently initiated first-in-human clinical trial at Paula Stradiņa Klīniskā universitātes slimnīca in Riga. The trial focuses on the safety and feasibility of the Sentante robotic system. For the first time various peripheral interventions such as balloon angioplasty, stent delivery, and embolization techniques were performed using the endovascular robotic system.
Sentante brings robotic safety, stability and accuracy to the patients, safe and effective work environment to the healthcare providers. Sentante is designed to enable physicians to perform an entire endovascular procedure from a remote workstation fully protecting all medical staff from radiation exposure. The system provides an ergonomic workspace and precise control with haptic force feedback, improving both physician’s comfort and procedural safety.
Prof. Dainis Krievins, MD, PhD, the principal investigator who performed the procedures, shared his thoughts: “The control of the system was great and I was surprised by the performance of the Sentante robotic system which provided excellent precision. Sentante has a huge potential to provide safer procedures for the patients and transform the hazardous work environment for medical personnel. This technology is a major step forward in our field, and I am confident it will further develop, enhancing patient care while also protecting doctors”.
“This achievement marks a significant milestone in our six-year journey, showing our commitment to bringing the Sentante system to a wider clinical use” said Edvardas Satkauskas, co-founder and CEO of Sentante.
“We are deeply grateful for Dainis Krievins, MD, PhD, Dr. Helmuts Kidikas, Martin Barons and the entire staff at Pauls Stradiņš Clinical University Hospital. Your exceptional contribution is instrumental in the success of our clinical study” said Dr. Tomas Baltrunas, co-founder and Chief Medical Officer of the Company.
The clinical validation data will be used for Sentante’s regulatory clearance. The company prepares to launch commercially in international markets next year.
About Sentante
Sentante is an innovative teleoperated robotic system developed by Lithuanian company UAB Inovatyvi Medicina. It allows an entire endovascular intervention to be performed remotely, from a different room, so physicians and the entire medical team can work without being exposed to harmful X-ray radiation.
Intuitively controlled via conventional endovascular devices Sentante senses operators’ movements and provides close to natural haptic force feedback – physicians can experience the same sensation of catheter and guidewire resistance as if they were physically present beside the patient.
In the future, Sentante will allow physicians to perform endovascular treatment from a remote hospital, eliminating the need for physical patient transfer. This innovation bears profound significance, particularly in critical cases such as stroke, where each passing minute significantly impacts the chances of a good outcome.
